Volume | 110,042 |
|
|||||
News | - | ||||||
Day High | 1.45 | Low High |
|||||
Day Low | 1.41 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Spero Therapeutics Inc | SPRO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.42 | 1.41 | 1.45 | 1.42 | 1.435 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
486 | 110,042 | $ 1.43 | $ 157,212 | - | 0.99 - 1.995 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:44:04 | 3 | $ 1.4206 | USD |
Spero Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
75.96M | 53.87M | - | 103.78M | 22.81M | 0.42 | 3.33 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Spero Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SPRO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.47 | 1.55 | 1.37 | 1.43 | 249,375 | -0.05 | -3.40% |
1 Month | 1.72 | 1.81 | 1.37 | 1.63 | 243,329 | -0.30 | -17.44% |
3 Months | 1.57 | 1.89 | 1.33 | 1.66 | 335,475 | -0.15 | -9.55% |
6 Months | 1.05 | 1.89 | 0.99 | 1.53 | 248,315 | 0.37 | 35.24% |
1 Year | 1.65 | 1.995 | 0.99 | 1.52 | 274,853 | -0.23 | -13.94% |
3 Years | 13.58 | 19.87 | 0.6801 | 2.36 | 962,116 | -12.16 | -89.54% |
5 Years | 12.48 | 23.639 | 0.6801 | 3.56 | 641,574 | -11.06 | -88.62% |
Spero Therapeutics Description
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital. |